NEW YORK (GenomeWeb News) – The US Food and Drug Administration has approved Abbott's hepatitis C virus genotyping test for marketing in the US, the company said today.

The Abbott RealTime HCV Genotype II, which Abbott is launching today, determines the specific type or strain of HCV present in the blood of an infected patient, allowing physicians to create a targeted diagnosis and treatment. The test differentiates genotypes 1, 1a, 1b, 2, 3, 4, and 5, FDA said separately.

The test runs on Abbott's m2000 platform.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.

Dec
03
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Dec
12
Sponsored by
Illumina

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.